Skip to main
  1. Stocks
  2. Nutex Health Inc
  3. Forecast
NUTX

NUTX Stock Forecast & Price Target

NUTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nutex Health is viewed favorably because the recent Fifth Circuit TMA III ruling and lower IDR fees should reduce “ghost rate” distortions, cut arbitration friction, and accelerate collections, while management already sees 80%+ collections and more than 85% win rates on disputed claims. The core business also looks attractive on unit economics: each hospital averages about $35M of revenue and roughly $10M of EBITDA, with high-40s to low-50s gross margins, low-30s EBITDA margins, and breakeven around 15 visits per day. Growth is further supported by a visible de novo pipeline of 10+ openings through 2028, expected low-teens 2027 revenue growth, strong cash generation of $248M in operating cash flow in 2025 and $109.7M in 1H26, and a net cash balance of $205.2M versus $39.7M of debt at June 30.

Bears say

Nutex Health is exposed to a fragile operating model where physician and nursing shortages, reimbursement cuts, and intensifying competition from retail clinics, telemedicine, and virtual visits can suppress patient volumes and strain revenue growth. Its dependence on out-of-network reimbursement through the federal IDR process creates significant earnings volatility, while adverse CMS rulemaking, litigation, or tighter regulatory scrutiny could compress award levels, reduce win rates, and limit the share of claims eligible for arbitration. Financially, the company’s results are hard to forecast because profitability is tied to lumpy arbitration-derived reimbursement, and execution or financing setbacks in sale-leaseback activity could weaken the balance sheet and slow capital recycling.

NUTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nutex Health Inc and is not a guaranteed prediction by Public.com or investment advice.

NUTX Analyst Forecast & Price Prediction

Get the latest NUTX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NUTX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nutex Health Inc (NUTX) Forecast

Analysts have given NUTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, NUTX has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $333, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $333, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nutex Health Inc (NUTX)


NUTX Analyst Forecast & Price Prediction

Get the latest NUTX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NUTX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NUTX stock data and trends